tbuckley/cabot-search huggingface dataset:
AB0715 THE PREVALENCE OF FIBROMIYALGIA IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND THE RELATIONSHIP BETWEEN FATIGUE AND QUALITY OF LIFE
Authors: S. Ugurlu, T. Civi Karaaslan, Z. Toker Dincer, E. Tarakci
Journal: Annals of the Rheumatic Diseases (2021)

Background: Familial Mediterranean Fever (FMF) can cause various muscle diseases. Because it is a chronic auto inflammatory disease, painful trigger points may be encountered in the examination due to a decrease in the pain threshold (1-3). Objectives: The aim of this study was to determine the prevalence of Fibromiyalgia in patients with FMF, at the same time to identify the relationship between fatigue and quality of life. Methods: Sixtyseven patients (38 female, 29 male) with FMF were enrolled in the study. They were diagnosed with FMF based on the Livneh diagnostic criteria (4). Fibromyalgia involvement of the patients was evaluated according to the Fibromyalgia Impact Questionnaire (FIQ). Patients with diagnose with other chronic disease were excluded. Fatigue Severity Scale (FSS) was used to evaluate fatigue. Quality of life was evaluated with Short Form-36 (SF-36). Results: Respectively, the mean age, disease duration and body mass index were 34.46±12.69 years, 12.66±7.86 years and 24.96±5.42 kg/m 2 . In addition, 65% of the patients had no rheumatic disease in their family history. The mean of scores of FIQ was 38.66±25.14, the mean of FSS was 38.07±17.56, the mean of SF-36-PCS was 45.55±10.54 and SF36-MCS was 30.93±17.39. Patients were categorized as mild (n=28), moderate (n=24) and severe (n=15) affected according to their FİQ score. The relationships of scores of FIQ, FSS and SF-36 were demonstrated Table 1. Conclusion: Fibromyalgia symptoms can be seen in FMF. According to our results, it has been shown that patients with moderate and severe symptoms have increased fatigue levels and decreased quality of life. In the light of these results, we can say that also the fibromyalgia symptom of patients with FMF should be considered in the treatment. References: [1]Sari, Ismail; Birlik, Merih; Kasifoglu, Timucin. Familial Mediterranean fever: an updated review. European journal of rheumatology, 2014, 1.1: 21. [2]Alayli G, Durmus D, Ozkaya O, Sen HE, Genc G, Kuru O. Frequency of juvenile fibromyalgia syndrome in children with familial Mediterranean fever: effects on depression and quality of life. Clin Exp Rheumatol 2011; 29: S127-32. [3]Langevitz P, Buskila D, Finkelstein R, Zaks N, Neuman L, Sukenik S, et al. Fibromyalgia in familial Mediterranean fever. J Rheumatol 1994; 21: 1335-7. [4]Bashardoust, Bahman. Familial Mediterranean fever; diagnosis, treatment, and complications. Journal of nephropharmacology, 2015, 4.1: 5. Table 1. The correlations of FIQ, FSS and SF-36 scores. FSS SF-36 PCS SF-36 MCS FIQ-mild mean±sd 23.78±14.88 53.34±7.01 40.98±13.73 r 0.595 ** -0.014 -0.551 ** p 0.001 0.944 0.002 FIQ-moderate mean±sd 45.75±10.83 41.09±8.89 38.13±9.19 r 0.053 -0.379 -0.145 p 0.806 0.068 0.498 FIQ-severe mean±sd 52.46±10.11 38.13±9.19 20.32±15.68 r 0.622 * -0.548 * -0.268 p 0.013 0.035 0.333 -Pearson Correlation Disclosure of Interests: None declared
Downregulation of NK cell activities in Apolipoprotein C-III-induced hyperlipidemia resulting from lipid-induced metabolic reprogramming and crosstalk with lipid-laden dendritic cells
Authors: Xiangyu Hu, Xiaoqin Jia, Cong Xu, Yingying Wei, Zhengbing Wang, George Liu, Qiang You, Guotao Lu, Weijuan Gong
Journal: Metabolism (2021)
Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States
Authors: Karen Seiter, Dominick Latremouille-Viau, Annie Guerin, Briana Ndife, Karen Habucky, George J Joseph, Irina Pivneva, Patrick Gagnon-Sanschagrin, Derek H Tang
Journal: Blood (2017)
Increased 68Ga-FAPI Uptake in Neurofibromatosis in a Patient With Pleomorphic Rhabdomyosarcoma
Authors: Junhao Wu, Yingwei Wang, Chunyin Zhang
Journal: Clinical Nuclear Medicine (2021)

A 48-year-old man presented with a painless enlarging mass on his right thigh for 2 months. He had a history of neurofibromatosis. MRI showed a mass in his right thigh. Malignant tumor was suspected. He was enrolled in the clinical trial of 68Ga-FAPI in solid tumors. Multiple increased FAPI uptake was observed in the right thigh mass, lung, and mediastinal lymph nodes, which were confirmed being pleomorphic rhabdomyosarcoma by biopsy. In addition, widespread metabolic activity was also observed in his cutaneous fibroma nodules. This case showed that benign neurofibromatosis can cause FAPI uptake.
Abstract 10946: Pitfalls in Ultrasound Evaluation of Left Atrial Appendage Mechanical Function Following Its Electrical Isolation
Authors: Carola Gianni, Javier E Sanchez, Qiong Chen, Domenico G Della Rocca, Bryan C MacDonald, Sanghamitra Mohanty, Chintan Trivedi, Amin Al-Ahmad, Mohamed A Bassiouny, J D Burkhardt, G J Gallinghouse, Rodney P Horton, Patrick M Hranitzky, Luigi Di Biase, Jorge Romero, Mario J Garcia, Andrea Natale
Journal: Circulation (2019)

Introduction: Following LAA electrical isolation, the decision on whether to continue anticoagulation after successful AF ablation is based on the study of its mechanical function on TEE. In this c...
AB0005 IDENTIFICATION OF KEY GENES AND PATHWAYS FOR PSORIASIS BASED ON GEO DATABASES BY BIOINFORMATICS ANALYSIS
Authors: X. Sun, S. X. Zhang, S. Song, T. Kong, C. Zheng, L. Cheng, S. Feng, G. Shi, X. LI, P. F. He, Q. Yu
Journal: Annals of the Rheumatic Diseases (2021)

Background: Psoriasis is an immune-mediated, genetic disease manifesting in the skin or joints or both, and also has a strong genetic predisposition and autoimmune pathogenic traits 1 . The hallmark of psoriasis is sustained inflammation that leads to uncontrolled keratinocyte proliferation and dysfunctional differentiation. And it’s also a chronic relapsing disease, which often necessitates a long-term therapy 2 . Objectives: To investigate the molecular mechanisms of psoriasis and find the potential gene targets for diagnosis and treating psoriasis. Methods: Total 334 gene expression data of patients with psoriasis research (GSE13355 GSE14905 and GSE30999) were obtained from the Gene Expression Omnibus database. After data preprocessing and screening of differentially expressed genes (DEGs) by R software. Online toll Metascape 3 was used to analyze Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of DEGs. Interactions of proteins encoded by DEGs were discovered by Protein-protein interaction network (PPI) using STRING online software. Cytoscape software was utilized to visualize PPI and the degree of each DEGs was obtained by analyzing the topological structure of the PPI network. Results: A total of 611 DEGs were found to be differentially expressed in psoriasis. GO analysis revealed that up-regulated DEGs were mostly associated with defense and response to external stimulus while down-regulated DEGs were mostly associated with metabolism and synthesis of lipids. KEGG enrichment analysis suggested they were mainly enriched in IL-17 signaling, Toll-like receptor signaling and PPAR signaling pathways, Cytokine-cytokine receptor interaction and lipid metabolism. In addition, top 9 key genes (CXCL10, OASL, IFIT1, IFIT3, RSAD2, MX1, OAS1, IFI44 and OAS2) were identified through Cytoscape. Conclusion: DEGs of psoriasis may play an essential role in disease development and may be potential pathogeneses of psoriasis. References: [1]Boehncke WH, Schon MP. Psoriasis. Lancet 2015;386(9997):983-94. doi: 10.1016/S0140-6736(14)61909-7 [published Online First: 2015/05/31]. [2]Zhang YJ, Sun YZ, Gao XH, et al. Integrated bioinformatic analysis of differentially expressed genes and signaling pathways in plaque psoriasis. Mol Med Rep 2019;20(1):225-35. doi: 10.3892/mmr.2019.10241 [published Online First: 2019/05/23]. [3]Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019;10(1):1523. doi: 10.1038/s41467-019-09234-6 [published Online First: 2019/04/05]. Acknowledgements: This project was supported by National Science Foundation of China (82001740), Open Fund from the Key Laboratory of Cellular Physiology (Shanxi Medical University) (KLCP2019) and Innovation Plan for Postgraduate Education in Shanxi Province (2020BY078). Disclosure of Interests: None declared
Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US
Authors: Bradley D. Stein, Brendan Saloner, Megan S. Schuler, Jill Gurvey, Mark Sorbero, Adam J. Gordon
Journal: JAMA (2021)

transplant recipients after dose 2 compared with dose 1, these data suggest that a substantial proportion of transplant recipients likely remain at risk for COVID-19 after 2 doses of mRNA vaccine.
POS1291 PROFILE OF LUMBAR SPINE DEGENERATIVE PATHOLOGY IN RHEUMATOLOGIC CONSULTATION IN NORTHEN TOGO
Authors: P. Houzou, V. E. S. Koffi-Tessio, E. Fianyo, K. Tagbor, K. Kakpovi, O. Oniankitan, M. Mijiyaw
Journal: Annals of the Rheumatic Diseases (2021)

Background: Degenerative spine pathology is a common reason for consultation in rheumatology. The lumbar spine is the first seat. Objectives: To determine the epidemiological and semiological profile of degenerative lumbar spine damage in Kara. Methods: It was a cross-sectional study based on patient records who had consulted for a degenerative lumbar spine pathology in the rheumatology department of the CHU-Kara (Northen Togo) over a three-year period. Results: Of the 1,767 patients examined during the study period, 745 (42.16%) suffered from a degenerative pathology of lumbar spine. They were 285 men (38.3%), and 460 women (61.7%) H/F ratio of 0.62. Traders (30%), civil servants (12.5%), teachers (9.5%), and housewives (8.7%) were the most affected occupational categories. The average age of patients at the consultation was 50.6 ± 12.3 years, and the average duration of disease progression was 4.3 years ± 1.8 years. The clinical forms of degenerative lumbar spine damage were: common low back pain (194 cases; 26.04%), common lomboradiculalgia by probable disco-radicular conflict (457 cases; 61.34%) and the narrowed lumbar canal (94 cases; 12.62%). Common low back pain was acute in 56.7% of cases. The path of radiculalgia during the probable herniated disc was truncated in 19.2% of cases, L5 in 46.4% of cases, S1 in 32.9% of cases, and L4 in 2.7% of cases. The walking perimeter was less than 500 meters in 48% of patients with narrowed lumbar canal. Signs of degenerative disc disease (536 cases), spondylolisthesis (102 cases) and isthmic lysis (37 cases) were the main radiological lesions observed. Conclusion: Degenerative damage to lumbar spine is dominated in North Togo by common lomboradiculalgia by probable herniated disc. References: [1]Mijiyawa M, Oniankitan O, Kolani B, Koriko T. La lombalgie en consultation hospitalière à Lomé (Togo). Rev Rhum 2000;67:914-20. [2]Louw QA, Morris LD, Grimmer-Somers K. The prevalence of low back pain in Africa: a systematic review. BMC Musculoskelet Disord 2007;8:105. [3]Morris LD, Daniels KJ, Ganguli B, Louw QA. An update on the prevalence of low back pain in Africa: a systematic review and meta-analyses. BMC Musculoskelet Disord 2018;19:196. [4]Ouédraogo D-D, Ntsiba H, Tiendrébéogo Zabsonré J, Tiéno H, Bokossa LIF, Kaboré F, et al. Clinical spectrum of rheumatologic diseases in a department of rheumatology in Ouagadougou (Burkina Faso). Clin Rheumatol 2014;33:385-9. Disclosure of Interests: None declared
Pericardial Fat and the Risk of Heart Failure
Authors: Satish Kenchaiah, Jingzhong Ding, J. Jeffrey Carr, Matthew A. Allison, Matthew J. Budoff, Russell P. Tracy, Gregory L. Burke, Robyn L. McClelland, Andrew E. Arai, David A. Bluemke
Journal: Journal of the American College of Cardiology (2021)
68Ga-DOTATATE PET/CT Distinguishes Neuroendocrine Tumor Mesenteric Lymph Node Metastasis From an Extensive IgG4-Positive Fibrosis Surrounding It
Authors: Niloefar Ahmadi Bidakhvidi, Pieter-Jan Cuyle, Xavier Sagaert, Florence Ballaux, Christophe M. Deroose
Journal: Clinical Nuclear Medicine (2021)

A 56-year-old woman presented with right iliac fossa pain. Abdominal CT showed a mesenteric mass in the right iliac fossa, adjacent to the vena cava inferior and right ureter. Biopsy of the mass revealed a well-differentiated neuroendocrine tumor. 68Ga-DOTATATE PET/CT showed strong somatostatin receptor expression only within in a small, central area of this mesenteric mass, with faint 68Ga-DOTATATE uptake in the majority of this mesenteric mass. Pathology revealed an IgG4-positive storiform fibrosis surrounding a mesenteric adenopathy. 68Ga-DOTATATE PET/CT discriminates between neuroendocrine tumor lymph node metastases and fibrosis, hereby avoiding potential sampling error of tumor biopsies and guiding surgical approach.
AB0236 DOWN-TITRATION STRATEGY OF TUMOR NECROSIS FACTOR-INHIBITOR AGENTS FOR RHEUMATOID ARTHRITIS IN TUNISIA
Authors: K. Saadaoui, H. Sahli, S. Boussaid, J. Samia, R. Sonia, C. Elhem, E. Mohammed
Journal: Annals of the Rheumatic Diseases (2021)

Background: Tumor necrosis factor (TNF) blocking agents are effective in treating rheumatoid arthritis, but they are associated with several adverse effects and high costs. Some studies have assessed the effectiveness of down-titration compared with continuation of standard dose. Objectives: The aim of our study is to assess dose tapering in Tunisia. Methods: A retrospective study including 170 rheumatoid arthritis patients treated by TNF blocker agent and with either low disease activity or remission (ACR/EULAR criteria). Two groups were compared, in the first group (G1) the interval of TNFi administration was extended, in the second group (G2) the standard dose and rhythm of administration were maintained. Results: The TNFi tapering group (G1) included 96 persons whereas the group having the same drug administration rhythm (G2) included 74 case. The baseline age of the down-dosing drug group was 56.6 ± 12.6 years versus 52.9 ± 11.6 years in the other group (p = 0.046) and the average disease duration were respectively 12.3 ± 7.2 years versus 11.2 ± 6 years (p = 0.346). Women represented 88.5% in G1 versus 93% in G2 (p = 0.298). Rheumatoid Factors and ACPA were positive respectively in (85.5% versus 83.8; p = 0.748) and (76.4% versus 67.8%; p= 0.309). Etanercept, adalimumab, certolizumab pegol and infliximab were respectively used in 84.4%, 9.4%, 4.2% and 2.1% cases (G1), whereas they were used in 48.6%, 16.2%, 27% and 8.1% cases in the second group (G2). In the TNFi down dosing group, methotrexate was associated to TNFi in 74% cases while 71.6% of patient received methotrexate in the standard rhythm of administration group (p = 0.734). Corticosteroids were used by 40.6% of patients in G1 vs. 56.8% of patients in G2 (p = 0.037). The average DAS 28 at baseline was 5.91 ± 0.81 (G1) versus 5.95 ± 0.80 (G2) (p = 0.759). There was no statistically significant difference between the two groups for rates of TNFi withdrawal (p = 0.798). In fact, TNFi was interrupted due to inefficacy for 17 patients (17.7%) in the down-dosing group versus 12 patients (16.2%) in the other group. Conclusion: Our study add evidence that TNFi drugs tapering could be equivalent to maintenance strategy. This could be beneficial to decrease the risk of adverse effect or reduce costs. Further studies are needed to confirm those results and identify patients who could benefit of TNFi administration rhythm step-down. Disclosure of Interests: None declared
Neuronal excitation/inhibition imbalance: core element of a translational perspective on Alzheimer pathophysiology
Authors: Fernando Maestú, Willem de Haan, Marc Aurel Busche, Javier DeFelipe
Journal: Ageing Research Reviews (2021)

Our incomplete understanding of the link between Alzheimer's Disease pathology and symptomatology is a crucial obstacle for therapeutic success. Recently, translational studies have begun to connect the dots between protein alterations and deposition, brain network dysfunction and cognitive deficits. Disturbance of neuronal activity, and in particular an imbalance in underlying excitation/inhibition (E/I), appears early in AD, and can be regarded as forming a central link between structural brain pathology and cognitive dysfunction. While there are emerging (non-)pharmacological options to influence this imbalance, the complexity of human brain dynamics has hindered identification of an optimal approach. We suggest that focusing on the integration of neurophysiological aspects of AD at the micro-, meso- and macroscale, with the support of computational network modeling, can unite fundamental and clinical knowledge, provide a general framework, and suggest rational therapeutic targets.
POS1237 ALGORITHM IDENTIFYING CHRONIC INFLAMMATORY DISEASES TREATED BY BIOTHERAPY AND/OR TARGETED SYNTHETIC TREATMENTS IN OUTPATIENT CARE IN FRANCE: FEASIBILITY, PRELIMINARY RESULTS, AND IMPACT OF COVID-19
Authors: P. Richette, M. Allez, V. Descamps, L. Perra, S. Pilet, M. Maravic
Journal: Annals of the Rheumatic Diseases (2021)

Background: Discriminating chronic inflammatory diseases under biotherapy and/or targeted synthetic treatments (B/TST) using medico-administrative databases are challenging but required for medico-economic analyses focusing on these diseases. Objectives: The objective was to evaluate the feasibility of using a medication dispense data in order to identify patients with chronic inflammatory diseases under B/TST in outpatient care setting and evaluate the impact of COVID-19 in France Methods: LRx contains all anonymized medication dispenses prescribed in outpatient care in a representative panel of French retails pharmacies, including data of near 40 million patients. Patients having at least one B/TST delivered in 2019 were selected. An algorithm was constructed using different steps, including a machine learning step by transfer learning applied in patient classified as having a rheumatologic condition in order to differentiate rheumatoid arthritis (RA) from spondyloarthritis (SA). We numbered 190,640 patients, of which 87.8% were classified in one of the following diseases: RA, SA, psoriatic arthritis (PA), psoriasis, inflammatory bowel diseases (IBD) (extrapolated data to France). Descriptive analysis was performed. The impact of COVID-19 on biotherapy initiation was evaluated during the lockdown period (W2-W19 2020) in these different conditions. Results: Among the 167,468 patients under B/TST, 20.7%, 18.4%, 6.5%, 37.9% and 16.5% were considered as having a psoriasis, IBD, PA, RA, and SA, respectively. Female patients were more frequent in RA and PA (&gt; 60%); younger (&lt; 20 years) and older patients (74 years) were found in patients with IBD (5.7%) and RA (12.6%), respectively. Contrasting with IBD, SA, and RA patients were mainly under anti-TNF treatment (&gt; 90% for IBD and SA, 73.5% for RA), psoriasis and PA patients received a range of broadly well-balanced of B/TST. Among the immunosuppressant, methotrexate was mostly prescribed in RA (58.4%), PA (34.1%), and psoriasis (14.1%), and azathioprine in IBD (19.9%). Oral corticosteroid delivered at least 4 times in 2019 were mostly found to be associated with a RA condition (28%). A significant decrease of biotherapy initiation was observed during the lockdown in France in patients with IBD (-20%, p=0.03) and psoriasis (-54%, p&lt;0.0001), not significant decrease in patients with SA (-6%) and increase in RA patients (+23%). Conclusion: The algorithm was able to identify patients with chronic inflammatory diseases under B/TST delivered in outpatient care and will allow to follow-up its management and study the COVID-19 impact on biotherapy initiation. An external validation needs to be performed Disclosure of Interests: None declared
POS1224 RHEUMATIC MANIFESTATIONS IN COVID-19 PATIENTS - SINGLE-CENTER EXPERIENCE AMIDST THE PANDEMIC
Authors: S. Bogdanova-Petrova, T. Georgiev, G. Gerganov, S. Hristova, S. Dimitrov, T. Shivacheva
Journal: Annals of the Rheumatic Diseases (2021)

Background: Recently evolved from a monochromic flu-like disease to a polysyndromic “spectrum of disease”, our understanding of coronavirus disease 2019 (COVID-19) is still far from being complete [1]. Hyperinflammation involving not only the lungs but also the musculoskeletal system, skin, cardiovascular, genitourinary systems is immune-mediated resembling the flares of a full-blown rheumatic disease [2,3]. Objectives: To describe the prevalence and type of rheumatic manifestations in a cohort of COVID-19 patients hospitalized in the COVID-19 rheumatology department in University Hospital St. Marina, Varna, Bulgaria. Methods: In the present single-center cohort study, а retrospective database analysis was performed among all COVID-19 patients hospitalized from 1 Dec 2020 to 22 Jan 2021. All 243 patients (age 19 - 93 years) were treated for moderate or severe SARS-CoV-2 infection confirmed by laboratory tests, including positive polymerase chain reaction (PCR) test, and imaging modality. Inpatient treatment included antibiotics, dexamethasone, anticoagulants, and antiviral drug remdesevir (optional). Detailed disease history and clinical examination were carried out by a fully certified rheumatologist and/or specialist in internal medicine. Results: Among all 243 COVID-19 patients, those with prominent self-reported myalgia and arthralgia were 26% (n = 63) and 21.3 (n = 52), respectively. We had 4 (1.6%) cases of newly developed cutaneous vasculitis and 2 (0.8%) cases of severe Raynaud’s phenomenon after SARS-CoV-2 infection onset. Two patients experienced severe muscle weakness, had elevated creatine phosphokinase, and were diagnosed with inflammatory myopathy secondary to COVID-19. Lupus-like syndrome was observed in 2 (0.8%) patients. Conclusion: Rheumatic manifestations are part of the heterogeneous spectrum of COVID-19 disease. Amidst the COVID-19 crisis, each newly onset rheumatic manifestation warrants exclusion of SARS-CoV-2 infection. Therefore, a rheumatologist should be a part of a multidisciplinary approach towards the COVID-19 treatment. References: [1]Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020;39(7):2055-2062 [2]Georgiev T, Angelov AK. Complexities of diagnosis and management of COVID-19 in autoimmune diseases: Potential benefits and detriments of immunosuppression. World J Clin Cases. 2020;8(17):3669-3678 [3]Ciaffi J, Meliconi R, Ruscitti P, Berardicurti O, Giacomelli R, Ursini F. Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. BMC rheumatology. 2020 Dec;4(1):1-5. Disclosure of Interests: None declared